This webinar examines Japan's Pricing & Market Access (P&MA) environment in the context of the US Most Favored Nation (MFN) policy. Drawing on recent policy developments and pricing and reimbursement outcomes for innovative medicines, it will provide insights into Japan’s role in the global pricing landscape and strategies for optimizing launch pricing and market access outcomes.
Participants will learn:
- How Japan's drug prices could affect global pricing through international reference pricing (IRP) under MFN
- How Japan's P&MA environment has responded to MFN, including payer and industry perspectives and recent policy changes
- Recent pricing and reimbursement outcomes for innovative medicines in Japan and the factors shaping those results
- How pharmaceutical and biotech companies optimize launch pricing and maximize value within Japan’s evolving pricing framework
By attending this webinar, participants will gain a comprehensive understanding of the evolving P&MA landscape in Japan, and strategies to optimize launch pricing and market access success in Japan while supporting global pricing objectives.
This event is free of charge.
